← Browse by Condition
Medical Condition

adverse effects

Total Trials
1
Recruiting Now
1
Trial Phases
Phase 2
NCT06936566 Phase 2
Recruiting

MAGIC Ruxolitinib for aGVHD

Enrollment
98 pts
Location
United States
Sponsor
John Levine
View Trial →